The Effect of Potassium Lowering Drugs on Cardiac Electrical Stability in Hemodialysis Patients (ART Study)

PHASE4RecruitingINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

February 14, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Potassium ImbalanceCardiac ArrhythmiaDialysis; Complications
Interventions
DRUG

sodium zirconium cyclic silicate

On the non-dialysis day, the drug was given to patients in the treatment group, four times a week, starting from 5g/day each time, and the blood potassium before dialysis was maintained at 4.0-5.0mmol/L, which could be adjusted at 10g/week each time, and the highest dose could be increased to 80g/ week.

Trial Locations (1)

100000

RECRUITING

Peking University first hospital hemodialysis center, Beijing

All Listed Sponsors
lead

Peking University First Hospital

OTHER